Development of a nanoparticle-based influenza vaccine using the PRINT® technology

Herein we describe the use of the PRINT® (Particle Replication in Non-wetting Templates) technology to deliver influenza vaccine antigens on a bioabsorbable particle. Poly (lactide-co-glycolide) PRINT particles were designed to electrostatically bind commercial trivalent injectable influenza vaccine. In a variety of formulations, these particles were safe and showed enhanced responses to influenza hemagglutinin in murine models. This program on a simple bioabsorbable particle could establish the PRINT technology for future and more complex vaccines, drug delivery, and areas of unmet medical needs.463